Publications

1. GVS advice to include the relugolix in combination with oestradiol and norethisteronacetate (Ryeqo®) combination

   The National Health Care Institute has completed its assessment whether relugolix in combination with oestradiol and ...

   Report | 19-10-2022

2. Evaluation and reassessment of further conditions for fampridine (Fampyra®)

   The National Health Care Institute advises the Minister that the fampridine (Fampyra®) conditions be revised and that the annual ...

   Report | 17-10-2022

3. Package advice atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

   The National Health Care Institute advises the Minister to include atidarsagene autotemcel (Libmeldy®) in the basic health care ...

   Report | 27-09-2022

4. GVS advice lenacapavir (Sunlenca®) for the treatment of HIV-1 infection

   The National Health Care Institute advises the Minister to include lenacapavir (Sunlenca®) on List 1B of the Medicine ...

   Report | 22-09-2022

5. Package advice on pegcetacoplan (Aspaveli®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH)

   The National Health Care Insititute has completed its assessment whether pegcetacoplan (Aspaveli®) can be included in the basic ...

   Report | 16-09-2022

6. Package advice brexucabtagene autoleucel (Tecartus®) refractory mantle cell lymphoma

   The National Health Care Institute advises the Minister not to include brexucabtagene autoleucel (Tecartus®) in the basic health ...

   Report | 09-09-2022

7. Package advice sacituzumab govitecan (Trodelvy®) for the treatment of inoperable or metastasized triple-negative breast cancer

   The National Health Care Institute advises the Minister to include sacituzumab govitecan (Trodelvy®) in the basic health care ...

   Report | 29-07-2022

8. GVS advice testosterone undecanoate (Nebido®)

   The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...

   Report | 21-07-2022

9. Package advice risdiplam (Evrysdi®) for the treatment of 5q spinal muscular atrophy (SMA)

   The National Health Care Institute advises the Minister to include risdiplam (Evrysdi®) in the health insurance package for the ...

   Report | 15-07-2022

10. GVS advice setmelanotide (Imcivree®)

    The National Health Care Institute advises the Minister to include setmelanotide (Imcivree®) in List 1B of the GVS. Setmelanotide ...

    Report | 08-07-2022